supplementation in haemodialysis patients. No significant adverse reactions to iron therapy were observed. Background. The aim of this prospective study was to test a new protocol for iron supplementation in haemoKey words: erythropoietin; ferritin; haemodialysis; iron; dialysis patients, as well as to assess the utility of intravenous different iron metabolism markers in common use and their 'target' values for the correction of iron deficiency. Methods. Thirty-three of 56 chronic haemodialysis patients were selected for long-term (6 months) i.v. Introduction iron therapy at 20 mg three times per week postdialysis based on the presence of at least one of the With the widespread utilization of rHuEpo in haemofollowing iron metabolism markers: percentage of dialysis, prolonged or chronic iron overload and transferrin saturation (%TSAT ) <20%; percentage of haemosiderosis have almost disappeared. Eryhypochromic erythrocytes (%HypoE ) >10% and thropoietin promotes the use of iron deposits in the serum ferritin (SF ) <400 mg/l. Reasons for patient bone marrow, and consequently iron deficiency is a exclusion were active inflammatory or infectious dis-frequent problem resulting in resistance to the full eases, haematological diseases, psychosis, probable effect of rHuEpo. It is well known that a negative iron iron overload (SF Á400 mg/l ) and/or acute need of balance may occur-up to 2 g/year [1]-and it is not blood transfusion mostly due to haemorrhage and well established whether there is a compensatory change in renal replacement treatment.
Patients and methods
without the above referred exclusion criteria, enrolling 33 patients into the study. If we had used a more restrictive Study design criterion (SF <100), 16 patients would not have been treated.
In a haemodialysis unit with 56 patients, 33 subjects meeting Iron administration and rHuEpo adjustment at least one of the following criteria: percentage of transferrin saturation (%TSAT ) <20%; percentage of hypochromic Iron saccarate ( VenoferA) 20 mg, diluted in 10 cc of saline erythrocytes (%HypoE) >10% and serum ferritin (SF ) was administered by the i.v. route during the last 10 min of <400 mg/l, were prospectively selected to initiate iron i.v. each dialysis treatment. All patients discontinued oral iron. therapy. The serum ferritin cut-off was arbitrarily chosen Criteria to stop the i.v. iron administration were allergic because there is no consensus regarding the target level of reaction; intolerable symptoms like metal taste, pruritus, ferritin in the published literature [13] [14] [15] . In order to paraesthesia, numbness; hepatic, pancreatic, or cardiac dysdetermine the level of ferritin under which there would be function, and increase of SF to values over 600 mg/l. With still response to iron, patients were divided into two groups reference to the latter, iron was resumed if SF fell to values based on ferritin level: Group I with baseline SF <100 mg/l less than 400 mg/l. and Group II with baseline SF Á100 mg/l and <400 mg/l.
The dose of rHuEpo was adjusted whenever haemoglobin The other 23 patients were excluded because of active increased to values above 12.5 g/dl. inflammatory or infectious disease (4), haematological disease (3-chronic lymphocytic leukaemia, aplastic anaemia,
Laboratory monitoring
and thalassaemia major), psychosis (1), probable iron overload (SF Á400 mg/l ) and/or acute need of blood transfusion
The percentage of transferrin saturation was determined mostly due to haemorrhage (13) and change of renal replaceusing the following formula: %TSAT=(serum iron× ment treatment (2). 100)/(transferrin×1.27). The percentage of hypochromic In addition to the routine follow-up procedures of the erythrocytes was calculated by determining the haemoglobin unit, blood cell count with %HypoE, serum iron, transferrin concentration of each erythrocyte using light-scattering and SF were evaluated in all patients. equipment with two reading angles (Technicon Mod. H2 We considered an increase of at least 1 g/dl of haemoglobin System). Samples were processed within 60 min. Serum ferriover the initial value as a positive response to iron therapy.
tin was determined by enzyme-linked fluorescent assay We observed in our population of patients that this was the (ELFA). Serum iron was determined by colorimetric method minimum change that made different two means of haemowithout deproteinization (FerroZineA chromogen). All these globin significant.
assays were subjected to daily standard procedures of quality control.
Patients Statistics
Thirty-three patients (13 females and 20 males) concluded the study. 
Results

Utility of iron markers Selection of patients for i.v. iron treatment out of the total 56 of the unit
Iron deficiency was diagnosed in every case showing an increase of at least 1 g/dl in the haemoglobin level Twelve patients had percentage of transferrin saturation after i.v. iron treatment; 29 of 33 treated patients <20%. All of them had SF less than 400 mg/l and only one responded positively.
had a percentage of hypochromic erythrocytes above 10%. Table 1 shows a sensitivity of 100% and a specificity One patient was excluded because of probable iron overload of 87.9% in the patients selected by ferritin <400 mg/l.
(SF=877 mg/l ) and recent transfusions, two had haematologThe overlapping of these criteria must be emphasized, ical diseases, and one had psychiatric disease.
i.e. all patients with SF <400 includes all the patients Hypochromic erythrocytes were above 10% in seven patients. Every patient had SF <400 mg/l and one had with %TSAT <20 and %HypoE >10. transferrin saturation <20%. Four patients were excluded based on probable iron overload (SF=877 mg/l ) and recent Haemoglobin evolution
There was a progressive increase in the mean value of and haematological disease (1).
Target ferritin levels are not well established [13] [14] [15] . haemoglobin from 10.8 g/dl±1.0 at the beginning to Table 1 . Sensitivity and specificity of iron markers ferritin' (Group I, SF <100 mg/l ) and 'high initial ferritin' (Group II, SF between 100 and 400 mg/l ).
False
False Sensitivity Specificity ferritin' had higher basal transferrin levels and until the 4th month. The percentage of transferrin saturation was identical in both groups at baseline, but was higher 12.8±0.9 g/dl at 6 months (P<0.0001). The increases in group I at the end of the study. The percentage of were always significant between the basal mean, the hypochromic erythrocytes was identical in both groups 2nd month, 4th month and 6th month ( Table 2) .
throughout the entire study. Group I required a lower dose of rHuEpo during the whole study and the Iron status evolution (Table 2) difference almost reached statistical significance (P<0.07) by the 6th month. Serum ferritin levels increased from 137 mg/l baseline to 456 mg/l (P=0.0001) at 6 months. Between the 4th and 6th month, the increment did not reach statistical Previous use of oral iron significance and, therefore, a 'plateau' may have been reached by the 4th month. Serum iron remained stable Twenty of the 33 treated patients had a prescription between 65 and 70 mg/dl without any significant vari-of oral iron. However, their mean ferritin values ation over the whole study period. Transferrin levels (130±106 mg/l ) did not differ significantly from those were decreased at the 2nd month (P<0.0001) and who were not on oral iron (147±106 mg/l ). Also the remained stable thereafter. The percentage of transfer-increases in haemoglobin and in ferritin were not rin saturation, after a significant initial rise, also stabil-different between patients with or without a prescripized. The percentage of hypochromic erythrocytes had tion for oral iron before the study. a similar evolution; a decrease at the 2nd month with no significant change in the remaining period.
We did not find any correlation between serum Suspension of i.v. iron ferritin and the percentage of transferrin saturation Twelve patients with ferritin >600 mg/l discontinued from the beginning to the end of the study. In the i.v. iron until serum ferritin levels declined to same way, no correlations were found between ferritin <400 mg/l. All of them were entirely free of any clinical and the percentage of hypochromic erythrocytes.
or biochemical dysfunction attributable to iron overload.
Erythropoietin use
The utilization of rHuEpo decreased from 6871 units/ patient/week to 4947 units/patient/week (28% change) Adverse reactions at 6 months (P<0.003). Consequently the dose/kg/ Four patients complained of 'metallic taste', mainly week of 118 units decreased to 84, providing a significwhen iron administration was too fast. There were no ant economic benefit. anaphylactic reactions, no skin rashes, and no signs of intestinal or respiratory allergy. We had no infectious Target ferritin complications throughout the study in patients on i.v. iron therapy. We did not observe any hepatic, pancreIn order to define a target value to maximize the use of i.v. iron, we compared patients with 'low initial atic or cardiac dysfunction related to iron treatment. readily available in the clinical laboratory. Recently The mean increase of 2 g/dl in haemoglobin values reticulocyte haemoglobin content has been proposed after 6 months of i.v. iron is the best argument to as a highly sensitive marker of functional iron defifavour the intravenous over the oral route. Oral iron, ciency [24], but we have no experience with it. Both prescribed to patients with the lowest serum ferritin traditional and more sophisticated new methods to values, was not useful to replenish their organ stores evaluate iron metabolism do not have an absolute of iron. On the contrary, patients who were not on sensitivity and specificity [25] . It is true that the oral iron had higher ferritin levels, although the differ-specificity of these criteria (%TSAT and %HypoE) was ence did not reach statistical significance. Based on very high, but if we really want to screen patients who this evidence, we conclude that oral iron was not would have some benefit from i.v. iron, we must use effective. Many nephrologists are aware that oral iron other more sensitive markers. It has been proved that administration is not always sufficient because iron the criterion serum ferritin <400 mg/l has a reasonable absorption can be abnormal in these patients [21] . sensitivity/specificity (100/87.9%) relationship, and our However, routine i.v. administration of iron is not results strongly recommend its use. widely accepted because of concern about allergic sideeffects and iron overload toxicity. We have no European data, but among United States haemodia-Target ferritin lysis patients receiving rHuEpo, the prevalence of iron This study corroborates others that suggest that the deficiency is more than 50% [22] . In fact there are criterion of serum ferritin <100 mg/l is too restrictive recent studies suggesting a decreased intestinal iron and insensitive to guide iron supplementation [14, 15] . absorption in uraemic patients, even in those with iron
The present study shows that a similar increase in deficiency [2,3], a finding not confirmed by others haemoglobin with iron therapy is obtained in patients [4, 5] . Additionally, a prospective controlled trial comwith serum ferritin between 100 and 400 mg/l and those paring i.v. iron, oral iron and placebo showed the with less than 100 mg/l. We found no significant adverse inefficacy of oral iron in haemodialysis patients with a reactions to iron therapy in patients with serum ferritin progressive decrease in iron deposits in the placebo bellow 600 mg/l. Higher values of serum ferritin were group as well as in the group on oral iron therapy [8] .
not studied at present and, therefore, no recommendations concerning the danger of iron overload can Utility of iron markers be made. With the i.v. iron protocol we used in this study, Only eight of the 33 patients selected for treatment had transferrin saturation of less than 20%. group I patients needed less rHuEpo (73. 4 units/kg/week) than those of group II (95.2 Considering that 29 patients responded to i.v. iron, and consequently had some degree of iron deficiency, units/kg/week) to reach the same haemoglobin values.
At baseline, group I had higher transferrin levels and we conclude that the sensitivity of this criterion is low (27.5%) ( Table 1 ). The percentage of hypochromic later developed higher serum iron and percentage of transferrin saturation. The two groups behave differerythrocytes, with a sensitivity of 10.3%, was of no utility to treat these patients (only 3 of 29 responders ently in the way they metabolize iron. It appears that patients with low initial ferritin are more capable of would be treated). It is possible that these two criteria may be useful to identify iron-deficient patients with utilizing iron, probably due to a genetic capability not present in the patients of group II. It would be inflammatory diseases with retention of iron in the reticuloendothelial system and high serum ferritin interesting to look at the prevalence of haemo-chromatosis alleles to determine whether there are Due to low sensitivity, the percentage of transferrin saturation and the percentage of hypochromic erythrodifferences between the two groups.
We cannot establish a 'normal' value for serum cytes were not useful parameters to assess iron requirements of haemodialysis patients. ferritin in haemodialysis patients. It seems probable that there is a wide range of individual variation and Patients with serum ferritin less than 100 mg/l had the same benefit in terms of haemoglobin increment as subpopulations with different behaviours regarding iron therapy and metabolism. However the goal of the ones with ferritin between 100 and 400 mg/l. No adverse effects of iron therapy were reported under optimal replenishment of iron stores must be fulfilled to obtain the maximal benefit of rHuEpo with the values of 600 mg/l.
We recommend administration of 20 mg of i.v. iron, minimal dose and side-effects. First we must exclude cases with iron overload or in which ferritin is not a which is monitored by monthly ferritin levels aiming at a target between 450 and 600 mg/l and, afterwards, good index of iron stores [16, 17] . Then, 20 mg iron i.v. should be administered after each dialysis session individualization of iron i.v. dose. The advantages of this protocol include more accurate iron administration and serum ferritin assessed on a monthly basis, trying to reach a stable 'plateau' of serum ferritin between and control, fewer rHuEpo side-effects, and cost, and possibly the prevention of aluminium intoxication. 450 and 600 mg/l. Whenever serum ferritin reaches values over 600 mg/l, i.v. iron should be stopped, and
We are aware that this is a single-centre study with a limited number of patients and should be confirmed restarted at half of the last dose once ferritin levels have decreased below 450 mg/l. This is the mean value by other multicentre prospective trials with larger numbers of patients. at which the best balance between haemoglobin concentration, rHuEpo dosage and serum ferritin values is achieved.
